TELA icon

TELA Bio

1.37 USD
+0.08
6.20%
At close Mar 27, 4:00 PM EDT
After hours
1.36
-0.01
0.73%
1 day
6.20%
5 days
-27.89%
1 month
-45.63%
3 months
-52.92%
6 months
-47.91%
Year to date
-52.43%
1 year
-75.58%
5 years
-82.90%
10 years
-89.74%
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

227,500% more call options, than puts

Call options by funds: $2.28M | Put options by funds: $1K

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

79% more capital invested

Capital invested by funds: $45.6M [Q3] → $81.6M (+$36.1M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

4% less funds holding

Funds holding: 49 [Q3] → 47 (-2) [Q4]

4.27% less ownership

Funds ownership: 72.9% [Q3] → 68.63% (-4.27%) [Q4]

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$2
46%
upside
Avg. target
$5.33
289%
upside
High target
$7
411%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Canaccord Genuity
Caitlin Cronin
29% 1-year accuracy
4 / 14 met price target
411%upside
$7
Buy
Maintained
21 Mar 2025
Citizens Capital Markets
David Turkaly
31% 1-year accuracy
8 / 26 met price target
411%upside
$7
Market Outperform
Maintained
21 Mar 2025
Piper Sandler
Matt O'Brien
45% 1-year accuracy
22 / 49 met price target
46%upside
$2
Neutral
Downgraded
21 Mar 2025

Financial journalist opinion

Based on 4 articles about TELA published over the past 30 days

Neutral
Seeking Alpha
1 week ago
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Greg Chodaczek - The Gilmartin Group Antony Koblish - Co-founder, President and Chief Executive Office Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens Matt O'Brien - Piper Sandler Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
1 week ago
TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.53 per share a year ago.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024.
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
4 weeks ago
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
2 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
3 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
4 months ago
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference.
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference
Neutral
Seeking Alpha
4 months ago
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago.
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
4 months ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™